Leerink Partners initiated coverage on ANI Pharmaceuticals (NASDAQ:ANIP) on Wednesday with an outperform rating.
The firm set a price target of $104.00 for the specialty pharmaceutical company.
This target suggests a potential upside of 48.08% from the previous closing price of $70.23.
ANI Pharmaceuticals currently maintains a consensus Moderate Buy rating from nine analysts.
Five analysts recommend a Buy and four assign a Hold rating to the stock.
The average price target among all analysts stands at $105.57.